Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced first patient enrollment into the pivotal U.S. REFRESH 2-AKI trial.

Thumbnail

Nicorandil protects older patients from myocardial injury after PCI

Intravenous nicorandil cut the risk of periprocedural myocardial injury (pMI) after percutaneous coronary intervention (PCI) by 49 percent among patients 65 and older, according to a substudy of a randomized trial published in PLOS One.

56% of readmissions after PCI attributed to noncardiac causes

Nearly one in 10 patients who receive percutaneous coronary intervention (PCI) end up back in the hospital with an unplanned readmission within 30 days, according to a study published online April 2 in JACC: Cardiovascular Interventions. These readmissions are usually for noncardiac causes and heavily linked to a patient’s comorbidities and place of discharge, the researchers found.

Hybrid revascularization comparable to CABG for treating multivessel CAD

A hybrid revascularization approach combining PCI and coronary artery bypass grafting (CABG) produced similar five-year outcomes compared to CABG alone, according to a randomized trial of patients with multivessel coronary artery disease (CAD) published in JACC: Cardiovascular Interventions.

Cardiva Medical® Announces FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure

Santa Clara, Calif. — April 5, 2018 — Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved for use in 5-7F femoral venous closures as well.

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

Thumbnail

Cardiologist argues for combination therapy for stroke, heart attack—but is anyone listening?

Victor Gurewich, MD, has spent more than two decades trying to spread the word about what he sees as an effective, lifesaving treatment approach to heart attack and stroke. At 88 years old, the cardiologist is hoping to breakthrough soon—and a new clinical trial in Europe could help.

Thumbnail

Genetic testing to inform antiplatelet choice reduces adverse events post-PCI

A genetic test to inform decisions about what antiplatelet to use following percutaneous coronary intervention (PCI) significantly reduced the number of major cardiovascular or cerebrovascular events in a single-center study published in Circulation: Genomic and Precision Medicine.

Displaying 953 - 960 of 2683

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.